STOCK TITAN
  1. Home
  2. News
  3. SNOA

Sonoma Pharmaceuticals, Inc. - SNOA STOCK NEWS

Welcome to our dedicated page for Sonoma Pharmaceuticals news (Ticker: SNOA), a resource for investors and traders seeking the latest updates and insights on Sonoma Pharmaceuticals stock.

Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) is a leader in the healthcare industry, specializing in the development and production of stabilized hypochlorous acid (HOCl) products. Operating globally, the company delivers innovative solutions for wound care, animal health care, eye care, oral care, and dermatological conditions. With products such as Epicyn, Levicyn, Celacyn Gel, SebuDerm, and Ceramax, Sonoma addresses various health concerns including infections, itch, pain, scarring, and inflammation.

The company’s flagship Microcyn® technology is backed by in-vitro and clinical studies, showcasing its antimicrobial, antiviral, and anti-inflammatory properties. Recent achievements include the launch of LumacynTM Clarifying Mist for over-the-counter use in the U.S., and an agreement with NovaBay Pharmaceuticals for the sale of Avenova®-branded products in the EU.

Sonoma Pharmaceuticals has its headquarters in Boulder, Colorado, with additional manufacturing operations in Guadalajara, Mexico, and European marketing and sales offices in Roermond, Netherlands. The company's products are available in 55 countries, either directly or through partners, and it continues to seek new distribution opportunities.

Financially, Sonoma reported a 7% increase in quarterly revenues to $3.2 million for the period ending December 31, 2023. U.S. sales saw a 14% increase, supported by strong demand for consumer-focused animal health care and wound care products. The company’s strategic investments in R&D and expansion of distributor networks have started to yield results, reflected in improved margins and reduced operating expenses.

For more information, visit the official website at www.sonomapharma.com or contact their customer service at 720-452-9690 or customerservice@sonomapharma.com.

News

Sonoma Pharmaceuticals Highlights Safety Advantages of its Microcyn Products in Light of Growing Concerns of Benzene in Many Other Topicals

Rhea-AI Summary
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) emphasizes the safety advantages of its Microcyn technology products over benzoyl peroxide-containing dermatology products. Recent concerns about benzene formation in popular dermatology products have led to a citizen petition for an FDA recall. Sonoma's Microcyn products, based on hypochlorous acid, are clinically proven to remove microorganisms safely and manage skin irritations without using benzoyl peroxide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.25%
Tags
none
-
News

Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2024 Financial Results

Rhea-AI Summary
Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA) reported a 7% increase in revenues compared to the previous year and a 15% increase from the prior quarter. The company also saw a 19% improvement in gross margin and a net loss of $1.0 million for the quarter. Sonoma's expansion efforts and cost control measures have positively impacted its financial results. The company also announced the launch of new products and partnerships, including Lumacyn Clarifying Mist and an agreement with NovaBay Pharmaceuticals, Inc. for the sale and marketing of Avenova-branded products in the European Union.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News

Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-the-Counter Skincare Product for Daily Use

Rhea-AI Summary
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) has announced the launch of LumacynTM Clarifying Mist, an anti-inflammatory and antibacterial spray for over-the-counter use in the United States. The product is based on Sonoma's patented stabilized hypochlorous acid and is designed to soothe the skin, reduce redness, manage blemishes, and is safe for all ages and skin types. The company aims to provide consumers with a premium skincare product that harnesses the healing properties of their Microcyn technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.25%
Tags
none
News

NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor Network

Rhea-AI Summary
NovaBay Pharmaceuticals, Inc. (NBY) and Sonoma Pharmaceuticals, Inc. (SNOA) have announced an agreement for the sale and marketing of Avenova-branded products in the European Union. Sonoma will combine its existing eye product Ocudox with Avenova branding and market it through its established European distribution network. Sonoma will pay NovaBay a royalty fee based on net product sales of Ocudox by Avenova, and Sonoma will continue to market its Ocudox product in the European Union.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor Network

Rhea-AI Summary
NovaBay Pharmaceuticals, Inc. (NBY) and Sonoma Pharmaceuticals, Inc. (SNOA) have announced an agreement for the sale and marketing of Avenova-branded products by Sonoma in the European Union. The products will combine Sonoma's existing eye product Ocudox with Avenova branding and will be marketed through Sonoma's established European distribution network. Sonoma will manufacture Ocudox by Avenova with packaging similar to NovaBay's Avenova products and will pay NovaBay a royalty fee based on net product sales. This agreement allows NovaBay to capitalize on sales of hypochlorous acid eye care products in the European Union, potentially doubling its sales of Avenova. NovaBay will continue to be the exclusive seller of Avenova branded products in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial Results

Rhea-AI Summary
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) announced a 36% gross profit percentage for the quarter, up 1% from the first fiscal quarter 2024. Total operating expenses decreased for the quarter and six months ended September 30, 2023, compared to the same period the prior year. European revenues increased 3% for the quarter and 13% for the six months ended September 30, 2023. The company reported a net loss of $2.9 million for the six months ended September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
News

Sonoma Pharmaceuticals Announces U.S. Launch of Next Generation Advanced Solution for Pulse Lavage Irrigation at the Symposium on Advanced Wound Care Fall Conference

Rhea-AI Summary
Sonoma Pharmaceuticals, Inc. has announced the U.S. launch of its intraoperative pulse lavage irrigation treatment. The product, developed using Sonoma's Microcyn® Technology, replaces non-antimicrobial saline and aggressive rinsing solutions with a safe and effective solution that can prevent infection and improve healing time. The treatment is cost competitive with IV bags and can be used in a variety of surgical procedures. Sonoma is introducing the product at the Symposium on Advanced Wound Care Fall Conference in Las Vegas and expects it to be ready for commercial use in November 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.76%
Tags
none
-
News

Sonoma Pharmaceuticals, Inc. Announces Pricing of $1.7 Million Public Offering of Common Stock

Rhea-AI Summary
Sonoma Pharmaceuticals, Inc. has announced the pricing of its public offering of 8,500,000 shares of common stock at $0.20 per share, expecting gross proceeds of approximately $1.7 million. The offering is set to close on October 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-48.65%
Tags
offering
-
News

National Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Sonoma Pharmaceuticals Reports First Fiscal Quarter 2024 Financial Results

Rhea-AI Summary
Sonoma Pharmaceuticals, Inc. announced financial results for its first fiscal quarter ended June 30, 2023. Revenue increased 6% compared to the same period last year, excluding a one-time event. Margins remained consistent year over year. Sonoma managed cash tightly, using only $0.3 million in its first fiscal quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3%
Tags
earnings

FAQ

What is the current stock price of Sonoma Pharmaceuticals (SNOA)?

The current stock price of Sonoma Pharmaceuticals (SNOA) is $2.64 as of January 23, 2025.

What is the market cap of Sonoma Pharmaceuticals (SNOA)?

The market cap of Sonoma Pharmaceuticals (SNOA) is approximately 3.6M.

What does Sonoma Pharmaceuticals specialize in?

Sonoma Pharmaceuticals specializes in the development and production of stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions.

What are some key products of Sonoma Pharmaceuticals?

Some key products include Epicyn, Levicyn, Celacyn Gel, SebuDerm, and Ceramax.

Where is Sonoma Pharmaceuticals headquartered?

The company is headquartered in Boulder, Colorado, with additional operations in Guadalajara, Mexico, and Roermond, Netherlands.

How did Sonoma Pharmaceuticals perform financially in the latest quarter?

For the quarter ending December 31, 2023, Sonoma reported a 7% increase in revenues to $3.2 million, driven by higher U.S. sales and increased demand for wound care products.

What recent product launches has Sonoma Pharmaceuticals announced?

Recent launches include LumacynTM Clarifying Mist and Microcyn Negative-Pressure Wound Therapy Solution in various sizes.

Who are some of Sonoma Pharmaceuticals' partners?

Sonoma partners with various companies including NovaBay Pharmaceuticals for the sale of Avenova®-branded products in the EU and Compana Pet Brands for distribution in North America.

In how many countries are Sonoma Pharmaceuticals' products available?

Sonoma’s products are available in 55 countries worldwide.

What technology is central to Sonoma Pharmaceuticals' product line?

The company's product line is centered around its patented Microcyn® technology, which is known for its antimicrobial, antiviral, and anti-inflammatory properties.

Where can consumers purchase Sonoma Pharmaceuticals' products?

Consumers can purchase products directly from Sonoma's website, on Amazon, and at various retail locations including Menards stores.

How can I contact Sonoma Pharmaceuticals for partnership opportunities?

For partnership opportunities, contact them at busdev@sonomapharma.com.
Stock SNOA logo
Sonoma Pharmaceuticals, Inc.

Nasdaq:SNOA

SNOA Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

SNOA Stock Data

3.60M
1.32M
1.51%
2.42%
5.97%
Drug Manufacturers - Specialty & Generic
Surgical & Medical Instruments & Apparatus
Link
United States of America
BOULDER